IL17RA and myeloid sarcoma: They were shown to be overexpressed in whole blood of RA patients [76], which is consistent with our results (Supporting Information S1), and in MS, IL17RA expression in PBMCs was described as being modulated during IFN-beta therapy in responders [39].